Novartis’ PREVENT trial of Cosentyx meets primary endpoint

Novartis intends to obtain approval for Cosentyx to treat nr-axSpA in the US and the EU. Credit: Novartis AG.



  • Novartis’ PREVENT trial of Cosentyx meets primary endpoint